/PRNewswire/ Solve Therapeutics, Inc. (SolveTx), a biopharmaceutical company developing novel antibody-based therapeutics, announces the acquisition of.
Cereius, a startup utilizing technology developed at Duke University focusing on radiodiagnostics and radiotherapeutics for use in cancer patients, has been sold. Here are the details.
Share this article
Share this article
SAN FRANCISCO, March 2, 2021 /PRNewswire/ Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, announced today that AbbVie, a leading global biopharmaceutical company, has purchased an exclusive right to acquire Mitokinin following completion of IND enabling studies on Mitokinin s lead PINK1 compound. Based on technology discovered at UCSF by Mitokinin co-founders Nicholas Hertz and Kevan Shokat, Mitokinin moved into MBC BioLabs San Francisco in September 2017 with Series A funding from a syndicate led by Mission BioCapital.
Mitokinin s novel PINK1 compounds selectively increase the activity of PINK1, a master regulator of mitochondrial quality control that is genetically linked to Parkinson s disease.